Charles Schwab Investment Management Inc. Reduces Holdings in Artivion, Inc. (NYSE:AORT)

Charles Schwab Investment Management Inc. cut its stake in Artivion, Inc. (NYSE:AORT) by 0.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 349,849 shares of the company’s stock after selling 1,722 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Artivion were worth $9,313,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of AORT. nVerses Capital LLC purchased a new stake in shares of Artivion in the 2nd quarter valued at about $28,000. RiverPark Advisors LLC purchased a new stake in Artivion in the second quarter valued at approximately $55,000. RW Investment Management LLC acquired a new stake in shares of Artivion in the second quarter valued at approximately $219,000. Intech Investment Management LLC purchased a new position in shares of Artivion during the second quarter worth approximately $253,000. Finally, XTX Topco Ltd acquired a new position in shares of Artivion in the 2nd quarter valued at $331,000. Institutional investors and hedge funds own 86.37% of the company’s stock.

Insiders Place Their Bets

In other Artivion news, VP Andrew M. Green sold 7,618 shares of the company’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $30.00, for a total value of $228,540.00. Following the transaction, the vice president now directly owns 33,503 shares in the company, valued at approximately $1,005,090. This represents a 18.53 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Amy Horton sold 4,329 shares of Artivion stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $29.66, for a total transaction of $128,398.14. Following the sale, the chief accounting officer now owns 135,660 shares of the company’s stock, valued at approximately $4,023,675.60. This trade represents a 3.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 24,377 shares of company stock worth $682,356. 8.10% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Oppenheimer increased their price target on shares of Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a research note on Friday, November 8th. JMP Securities assumed coverage on Artivion in a report on Wednesday, October 23rd. They set an “outperform” rating and a $33.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $34.00 price objective on shares of Artivion in a research note on Monday. Finally, Stifel Nicolaus increased their price objective on Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, September 13th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $31.80.

Artivion Trading Down 2.2 %

NYSE:AORT opened at $29.00 on Tuesday. Artivion, Inc. has a 1 year low of $16.48 and a 1 year high of $30.10. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.33 and a current ratio of 1.88. The stock has a fifty day moving average price of $27.43 and a two-hundred day moving average price of $26.07. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of -1,450.00 and a beta of 1.75.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.